What major milestone did Micro-X (ASX:MX1) recently achieve?

Micro-X has commenced its multi-centre pilot study and captured world-first Carbon Nanotube (CNT) Cone Beam CT human images using its curved array Head CT scanner.

How does this clinical trial milestone affect Micro-X’s balance sheet?

The commencement of the human imaging study and the successful completion of a test bench for a second trial site have triggered a $0.4 million milestone payment to Micro-X. While this provides an immediate cash injection, the company's long-term financial health will depend on commercialising the technology.

What is the main objective of the Micro-X (ASX:MX1) Head CT pilot study?

The prospective blind study is designed to evaluate the image quality and clinical utility of Micro-X’s miniaturised device against conventional, stationary hospital-based CT scanners.

What is the timeline and patient sample size for the Micro-X trial?

The blind clinical trial is expected to take six to nine months to complete. Researchers aim to image a sample size of 108 patients presenting with various brain pathologies, including ischaemic stroke, intracranial haemorrhage, brain tumours, and stroke mimic conditions.

What is management's long-term strategic vision for the Micro-X Head CT scanner?

Management and clinical partners aim to evolve the technology beyond traditional hospital radiology departments into a truly portable, miniaturised device. The ultimate goal is to deploy these scanners in the field, allowing emergency medical teams to reach and scan stroke patients wherever they are located.

Image for illustrative purposes only. Not a real photo.

Micro-X commences world-first brain imaging study

Written by Liezl GambePublished Jun 3, 2026, 6:31 AM

Micro-X (ASX:MX1) commenced its multi-centre pilot study, capturing world-first CNT Cone Beam CT human images using its curved array Head CT scanner at the Royal Melbourne Hospital.

The clinical trial signifies a major advancement in cold cathode X-ray technology, triggering a $0.4 million milestone payment to the company following the completion of a test bench for a second trial site.

The prospective blind study will evaluate image quality and clinical utility against conventional, hospital-based scanners.

Over the next six to nine months, researchers aim to image 108 patients presenting with various brain pathologies, including ischaemic stroke, intracranial haemorrhage, brain tumours, and stroke mimic conditions.

The initial real patient datasets generated during this first phase will be vital for refining imaging algorithms, specifically to identify neuroimaging-based contraindications to stroke thrombolysis.

Micro-X COO Anthony Skeats praised the milestone, noting it represents four years of relentless innovation and determination from the team as they look forward to completing the study and generating critical regulatory data.

Dr Anna Balabanski, lead clinical researcher and neurologist with the Australian Stroke Alliance, emphasised that this trial is an important step in evaluating the novel technology.

She highlighted the ultimate vision of seeing this miniaturised, portable device evolve beyond traditional hospital environments to reach stroke patients wherever they are located.

Trained radiographers are conducting the scans, which are integrated directly into the hospital's PACS network for blind analysis by the research team.

At the time of reporting, Micro-X’s share price was $0.038.